Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab plus weekly docetaxel in stage IV NSCLC after platinum therapy
2016-001317-25Phase 2Active
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2016
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ramucirumab and docetaxel in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Primary endpoint: Grade ≥3 neutropenia rate. Started Aug 2016; status: active.
02
Drugs
ramucirumabdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2016-001317-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001317-25.